SG Americas Securities
RPRX icon

SG Americas Securities’s Royalty Pharma RPRX Stock Holding History

SG Americas Securities’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.6M Buy
688,590
+392,251
+132% +$20.4M 0.02% 414
2026
Q1 		$14.2M Buy
296,339
+8,137
+3% +$356K 0.02% 670
2025
Q4 		$11.1M Buy
288,202
+234,629
+438% +$8.95M 0.01% 724
2025
Q3 		$1.89M Sell
53,573
-15,132
-22% -$548K 0.01% 981
2025
Q2 		$2.48M Buy
68,705
+15,218
+28% +$504K 0.01% 687
2025
Q1 		$1.67M Buy
+53,487
New +$1.7M 0.01% 870
2024
Q4 		– Sell
-62,131
Closed -$1.76M – 3544
2024
Q3 		$1.76M Buy
62,131
+53,008
+581% +$1.47M 0.01% 735
2024
Q2 		$241K Sell
9,123
-88,380
-91% -$2.45M ﹤0.01% 2080
2024
Q1 		$2.96M Buy
+97,503
New +$2.87M 0.01% 735
2023
Q4 		– Sell
-5,300
Closed -$144K – 3392
2023
Q3 		$144K Sell
5,300
-18,344
-78% -$545K ﹤0.01% 2531
2023
Q2 		$727K Buy
23,644
+11,910
+101% +$403K 0.01% 1218
2023
Q1 		$423K Buy
+11,734
New +$435K ﹤0.01% 1847
2022
Q4 		– Sell
-16,437
Closed -$660K – 3334
2022
Q3 		$660K Sell
16,437
-3,114
-16% -$133K 0.01% 1301
2022
Q2 		$822K Buy
19,551
+1,455
+8% +$59.6K 0.01% 1477
2022
Q1 		$705K Buy
+18,096
New +$711K 0.01% 1663
2021
Q4 		– Sell
-25,983
Closed -$939K – 3753
2021
Q3 		$939K Buy
25,983
+14,509
+126% +$564K ﹤0.01% 1968
2021
Q2 		$470K Sell
11,474
-22,925
-67% -$975K ﹤0.01% 1970
2021
Q1 		$1.5M Buy
34,399
+21,305
+163% +$1.01M 0.01% 1250
2020
Q4 		$655K Buy
+13,094
New +$556K ﹤0.01% 1784

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SG Americas Securities's RPRX Position: Q2 2026 in Review

SG Americas Securities increased its Royalty Pharma (RPRX) stake by 132% in Q2 2026, buying an estimated $20.4M and bringing the position to 688,590 shares worth $38.6M. The position accounts for 0.02% of the portfolio, ranked #414.

SG Americas Securities first reported a position in RPRX in Q4 2020 and has held it in 19 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • SG Americas Securities held 688,590 shares of Royalty Pharma worth $38.6M as of Q2 2026.
  • SG Americas Securities bought 392,251 Royalty Pharma shares in Q2 2026, an estimated $20.4M.
  • Royalty Pharma made up 0.02% of SG Americas Securities's portfolio in Q2 2026, its #414 holding.
  • SG Americas Securities first reported a position in Royalty Pharma in Q4 2020 and has held it in 19 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.